This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, C.
Right arrow Articles by Li, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, C.
Right arrow Articles by Li, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2008, p. 3967-3972, Vol. 52, No. 11
0066-4804/08/$08.00+0     doi:10.1128/AAC.00542-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Mucroporin, the First Cationic Host Defense Peptide from the Venom of Lychas mucronatus{triangledown}

Chao Dai,{dagger} Yibao Ma,{dagger} Zhenhuan Zhao, Ruiming Zhao, Qian Wang, Yingliang Wu, Zhijian Cao,* and Wenxin Li*

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China

Received 28 April 2008/ Returned for modification 3 July 2008/ Accepted 22 August 2008

The misuse of antibiotics has led our age to a dangerous edge, as antibiotic-resistant pathogens appear to evolve more quickly than antibiotics are invented. Thus, new agents to treat bacterial infection are badly needed. Cationic host defense peptides are on the first line of a host defense system and are thought to be good candidates for treating bacterial infection. Here, a novel cationic host defense peptide, mucroporin, was cloned and characterized from the venom of Lychas mucronatus. The MIC for Staphylococcus aureus was 25 µg/ml, including antibiotic-resistant pathogens. Based on the molecular template of mucroporin, mucroporin-M1 was designed by amino acid substitution. The MIC for S. aureus was 5 µg/ml, including the antibiotic-resistant pathogens methicillin-resistant S. aureus, methicillin-resistant coagulase-negative Staphylococcus, penicillin-resistant S. aureus, and penicillin-resistant S. epidermidis. Moreover, mucroporin-M1 also inhibited gram-negative bacteria. The modes of action of mucroporin and mucroporin-M1 were both rapid killing by disrupting the cell membrane of bacteria, and the number of surviving bacteria was reduced by about 4 to 5 orders of magnitude immediately after peptide delivery. These results showed that mucroporin could be considered a potential anti-infective drug, especially for treating antibiotic-resistant pathogens.

* Corresponding author. Mailing address: State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei 430072, China. Phone: 86-27-68752831. Fax: 86-27-68752146. E-mail for Z. Cao: zjcao{at}whu.edu.cn. E-mail for W. Li: liwxlab{at}whu.edu.cn

{triangledown} Published ahead of print on 8 September 2008.

{dagger} C.D. and Y.M. contributed equally to this study.

Antimicrobial Agents and Chemotherapy, November 2008, p. 3967-3972, Vol. 52, No. 11
0066-4804/08/$08.00+0     doi:10.1128/AAC.00542-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»